Literature DB >> 3874000

Treatment of advanced breast cancer with 5-fluorouracil and high-dose folinic acid: preliminary results.

G Marini, P Marpicati, A Zaniboni, G C Cervi, F Gorni, E Simoncini.   

Abstract

Twenty-eight patients with advanced breast cancer, all previously treated with hormonotherapy and/or chemotherapy, entered this study. Treatment was comprised of 5-day courses of folinic acid (200 mg/m2/day by i.v. bolus injection) and 5-fluorouracil, given immediately afterwards at a dose of 340-370-400 mg/m2/day according to toxicity. Cycles were repeated every 28 days. The remission rate was 60.7% (17/28): 10.7% CR (complete) (3/28), 50% PR (partial) (14/28), while 35% (1/28) had no change. Fourteen out of 23 patients previously treated with 5-FU also responded. The median duration of remission was about 6 months. Hematological toxicity was mild, while gastroenteric and ocular side-effects were important, even if not life-threatening. These data suggest that 5-FU combined with high-doses of folinic acid is effective in advanced breast cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874000

Source DB:  PubMed          Journal:  Chemioterapia        ISSN: 0392-906X


  3 in total

1.  A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.

Authors:  H Stöger; T Bauernhofer; M Schmid; F Ploner; R Moser; E Derstvenscheg; P Steindorfer; M Wilders-Truschnig; I Kuss; H Samonigg
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults.

Authors:  D J Stewart; S Dahrouge; K Soltys
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 3.  The effect of leucovorin on the therapeutic index of fluorouracil in cancer patients.

Authors:  R J DeLap
Journal:  Yale J Biol Med       Date:  1988 Jan-Feb
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.